Aurobindo Pharma Issues Nationwide Recall of Migraine Relief Tablets Due to Mislabeling
Aurobindo Pharma USA, Inc. has issued a voluntary nationwide recall of its Healthy Living Migraine Relief tablets due to serious mislabeling issues that could endanger consumer health. Sold primarily through Amazon, these acetaminophen, aspirin, and caffeine tablets lack essential over-the-counter labeling, raising concerns about safe usage. Consumers are urged to check their medicine cabinets and discontinue use if they have purchased the affected product. Stay informed about medication recalls to protect your health.
Diamond Shruumz Candies Under FDA Investigation Amid Illness and Death Reports
Diamond Shruumz microdosing candies are under investigation by the FDA following reports of severe illnesses and two deaths. With 74 cases reported across 28 states, health officials urge consumers to avoid these products. The investigation reveals potential links to toxic substances, including a synthetic psychedelic compound. Stay informed as authorities work to address this urgent public health crisis.
Wehah Farms Issues Recall for Lundberg Rice Due to Contamination Risk
Wehah Farms has issued a voluntary recall of 4,600 cases of Lundberg Family Farms Sustainable Wild Blend Gourmet Rice due to potential contamination with rodent parts. Affected products, packaged in 1-pound bags, have the lot code 231004 and a best before date of October 4, 2024. This Class II recall impacts consumers in Arizona, California, Florida, Maine, New Hampshire, Oregon, and Wisconsin. The FDA advises consumers to check their pantries and return any affected products for a refund.
FDA Study Reveals Concerning Levels of Bacteria in Tattoo and Permanent Makeup Inks
Recent FDA research reveals concerning findings about microbial safety of tattoo and permanent makeup inks. Contaminated ink can lead to serious infections and health risks, including systemic spread of bacteria. Proper monitoring and quality control are crucial to protect consumers from potential hazards.
FDA Escalates Recall of Inspire Medical’s Nerve-Stimulating Implant for Sleep Apnea
The FDA has issued a Class I recall for Inspire Medical’s nerve-stimulating implant used in treating obstructive sleep apnea due to a manufacturing defect. Despite no reported injuries, up to 32 devices may be impacted. Inspire Medical continues to expand its therapy offerings amidst the recall, with a projected revenue growth of 26% for 2024.
FDA Authorizes Cepheid’s Molecular Test for Hepatitis C Detection from Fingerstick Blood Samples
Cepheid has received de novo authorization from the FDA for a molecular test that can detect hepatitis C virus RNA directly from fingerstick blood samples, revolutionizing the healthcare industry. The Xpert HCV test, running on Cepheid’s Genexpert Xpress System, provides rapid results within one hour, eliminating the need for samples to be sent to central labs. This game-changing approval enables same-visit diagnosis and treatment, potentially increasing the number of hepatitis C patients being diagnosed and treated promptly.
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab
The FDA has approved Eli Lilly’s Alzheimer’s drug donanemab, now marketed as Kisunla, offering hope to the 7 million Americans affected by the disease. Donanemab targets toxic plaques in the brain to slow disease progression, competing with Biogen and Eisai’s Leqembi. Clinical trials showed a 35% reduction in Alzheimer’s progression over 18 months, with monthly infusions costing $12,522 for a six-month course.
CDC Recommends Covid-19 Vaccines for All Americans This Fall
CDC recommends all Americans ages 6 months and older receive new Covid-19 vaccines this fall as infections rise in 39 states. Vaccines offer incremental boost to waning immunity against evolving virus. Panel advises another round of immunizations to protect against current strains.
Bavarian Nordic Submits Chikungunya Vaccine for Approval in Europe
Bavarian Nordic has submitted its chikungunya vaccine for approval in Europe, following a similar application in the US. This strategic move aims to combat the spread of the mosquito-borne viral disease and improve global health initiatives. Stay tuned for updates on the potential approval in the first half of 2025.
Groundbreaking Discovery in Parkinson’s Disease Research
Groundbreaking research on Parkinson’s disease reveals potential FDA-approved treatment targeting cell surface protein Aplp1 and Lag3 to block spread of harmful material. Findings suggest promising therapy avenue already available, offering hope to millions worldwide.